Top Page
GH Research
(NASDAQ:GHRS)
GH Research (GHRS) vs. SPDR S&P 500 ETF (SPY)
GH Research Business Overview & Revenue Model
GH Research Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -335.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -60.34M | -38.60M | -35.21M | -22.41M | -9.17M |
| Net Income | -48.26M | -38.96M | -35.59M | -22.46M | -9.20M |
Balance Sheet | |||||
| Total Assets | 288.23M | 188.27M | 226.30M | 254.36M | 279.92M |
| Cash, Cash Equivalents and Short-Term Investments | 280.71M | 149.32M | 161.56M | 165.96M | 276.78M |
| Total Debt | 512.00K | 624.00K | 974.00K | 0.00 | 0.00 |
| Total Liabilities | 8.53M | 9.32M | 7.33M | 4.55M | 2.75M |
| Stockholders Equity | 279.70M | 178.95M | 218.97M | 249.82M | 277.18M |
Cash Flow | |||||
| Free Cash Flow | -43.67M | -42.33M | -33.44M | -26.27M | -15.39M |
| Operating Cash Flow | -43.55M | -42.28M | -33.34M | -26.20M | -15.28M |
| Investing Cash Flow | 46.17M | 65.14M | -54.10M | -84.69M | -104.00K |
| Financing Cash Flow | 139.65M | -304.00K | -204.00K | 0.00 | 286.45M |
GH Research Technical Analysis
GH Research Risk Analysis
GH Research Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $1.79B | -5.25 | -43.17% | ― | -16.50% | 33.02% | |
57 Neutral | $1.08B | 440.65 | 0.87% | ― | 26.54% | ― | |
53 Neutral | $1.25B | -16.13 | -56.64% | ― | -36.36% | -945.72% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $918.66M | -16.06 | -16.30% | ― | ― | 8.16% | |
50 Neutral | $664.43M | -2.57 | -178.61% | ― | 647.13% | 26.79% | |
46 Neutral | $845.97M | -4.22 | -141.99% | ― | ― | 31.16% |
GH Research Corporate Events
GH Research PLC reported on March 5, 2026, that it completed a successful Phase 2b trial of its inhaled mebufotenin candidate GH001 in treatment-resistant depression in 2025, demonstrating rapid and durable remission rates with a strong safety profile and short psychoactive exposure. The company is seeking U.S. FDA alignment on a global Phase 3 pivotal program, has an FDA clearance for U.S. clinical investigation of GH001, is advancing a proprietary aerosol delivery device to support pivotal trials, and ended 2025 with $280.7 million in cash and securities alongside a widened net loss driven by higher R&D and administrative spending.
For 2025, GH Research reported research and development expenses of $38.8 million and general and administrative costs of $22.0 million, contributing to a net loss of $48.3 million, or $0.79 per share, versus a $39.0 million loss a year earlier. The strengthened balance sheet and positive Phase 2b data position the company to fund its planned late-stage clinical program in TRD, potentially enhancing its standing in the emerging psychedelic-inspired depression treatment space if Phase 3 results can replicate these outcomes.
The most recent analyst rating on (GHRS) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.
On January 22, 2026, GH Research PLC announced it will participate in a virtual panel discussion at the RBC Capital Markets Psychedelics Symposium: A Trip Into The Future of Mental Health, highlighting its engagement with investors and industry stakeholders in the emerging psychedelic therapeutics space. The participation underscores the company’s efforts to raise its profile within capital markets and the broader mental health innovation community, potentially supporting visibility for its pipeline and strategy as the psychedelic medicine field continues to attract institutional attention.
The most recent analyst rating on (GHRS) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.
On January 15, 2026, GH Research announced that it would present results from three clinical trials of its investigational antidepressant GH001 at a mini‑panel during the 64th American College of Neuropsychopharmacology annual meeting, held January 12‑15, 2026 in Nassau, Bahamas. The session, chaired by psychiatrist Michael E. Thase, features data from a Phase 2b double‑blind, randomized, controlled trial with a six‑month open‑label extension in treatment‑resistant depression, as well as Phase 2a trials in postpartum depression and bipolar II depression, highlighting GH001’s rapid antidepressant effects, improvements in anhedonia and maternal functioning, favorable tolerability, and rapid elimination from breast milk; the high‑profile scientific forum underscores GH Research’s bid to position GH001 within the emerging class of rapid‑acting psychoactive therapies for hard‑to‑treat depressive disorders and may strengthen its visibility among clinicians, researchers and potential partners.
The most recent analyst rating on (GHRS) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.
On January 13, 2026, GH Research PLC announced that it would present clinical results from its Phase 2b GH001-TRD-201 trial in treatment-resistant depression at the Promising Targets Oral Session of the 64th American College of Neuropsychopharmacology annual meeting, held January 12–15, 2026, in Nassau, Bahamas. The ACNP presentation, delivered by Professor Michael E. Thase, highlights data indicating that GH001 improved illness severity, anxiety symptoms and quality of life over up to six months of follow-up, underscoring the candidate’s potential to address the substantial unmet need in treatment-resistant depression and reinforcing GH Research’s positioning among emerging developers of fast-acting psychedelic medicines.
The most recent analyst rating on (GHRS) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.
On January 8, 2025, GH Research PLC reported that it will present new clinical data from its GH001-TRD-201 and GH001-BD-202 trials at the 64th American College of Neuropsychopharmacology annual meeting, to be held January 12–15, 2026, in Paradise Island, Bahamas. The accepted posters cover Phase 2b results on rapid antidepressant effects of inhaled GH001 in treatment-resistant depression, detailed safety findings regarding suicidal ideation and behavior in TRD patients, and Phase 2a data in bipolar II disorder with a current major depressive episode. The TRD Phase 2b study, which included a 7‑day randomized, double-blind period followed by a six‑month open-label extension, found that GH001 was generally well tolerated, produced significant reductions in depressive symptoms and did not increase suicidal ideation or suicidal behavior over six months, with no treatment-emergent events involving suicidal intent or behavior and only one transient case of suicidal ideation. These findings, together with the broader program data being showcased at a major neuropsychopharmacology forum, underscore GH001’s potential as a rapid-acting antidepressant option for high-risk TRD and bipolar depression populations, addressing a significant unmet need for therapies that do not exacerbate suicide risk.
The most recent analyst rating on (GHRS) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.
On January 5, 2026, GH Research announced that the U.S. Food and Drug Administration lifted the clinical hold on its investigational TRD therapy GH001, clearing the drug for clinical investigation in the United States and enabling U.S. patient enrollment. The company plans to align with the FDA on a global Phase 3 program modeled on its Phase 2b trial, which previously met its primary endpoint with a strong MADRS score reduction, high rapid-remission rates, short treatment sessions, and a favorable safety profile, potentially strengthening GH Research’s competitive position in next-generation depression treatments and supporting the integration of GH001 into existing interventional psychiatry practices if later-stage data are positive.
The most recent analyst rating on (GHRS) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.
On January 2, 2026, GH Research PLC announced that it plans to provide an update on the status of its Investigational New Drug Application (IND) for its lead candidate GH001 with the U.S. Food and Drug Administration, along with details on its global pivotal Phase 3 program in treatment-resistant depression, on January 5, 2026. The planned update signals a key regulatory and clinical development milestone for the company, as progress on GH001’s IND and Phase 3 program will be central to its efforts to bring a potential practice-changing treatment for TRD to market and could materially influence its position in the competitive depression therapeutics landscape.
The most recent analyst rating on (GHRS) stock is a Hold with a $12.50 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.